Comparative Pharmacology
Head-to-head clinical analysis: GARAMYCIN versus GENTAFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GARAMYCIN versus GENTAFAIR.
GARAMYCIN vs GENTAFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, leading to bacterial cell death.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Gentamicin 3-5 mg/kg/day IV or IM in 3 divided doses every 8 hours for serious infections; may use once-daily dosing (5 mg/kg IV every 24 hours) for certain indications.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 40-50 hours in anuria).
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<2%).
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic